Efficacy and tolerability of oleylphosphocholine (OLPC) in a laboratory model of visceral leishmaniasis

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 11, 2012, Pages 2707-2712

  Fortin, Anny ^a,b   Hendrickx, Sarah ^c   Yardley, Vanessa ^d   Cos, Paul ^c   Jansen, Herwig ^a   Maes, Louis ^c  

^a Dafra Pharma Research and Development   (Belgium)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITY OF ANTWERP   (Belgium)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Hamsters; Leishmania infantum; Liposome formulations

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; ANTIMONY; CHOLINE DERIVATIVE; MILTEFOSINE; OLEYLPHOSPHOCHOLINE; PAROMOMYCIN; PHOSPHOLIPID DERIVATIVE; STIBOGLUCONATE SODIUM; UNCLASSIFIED DRUG; WATER;

AMASTIGOTE; ANIMAL CELL; ANIMAL EXPERIMENT; AQUEOUS SOLUTION; ARTICLE; BONE MARROW; CELL ASSAY; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENCY; DRUG SAFETY; DRUG SENSITIVITY; DRUG TOLERABILITY; HAMSTER; IC 50; IN VITRO STUDY; IN VIVO STUDY; LABORATORY; LEISHMANIA DONOVANI; LEISHMANIA INFANTUM; LEISHMANIA MEXICANA; LEISHMANIA PANAMENSIS; LEISHMANIA TROPICA; LIPOSOMAL DELIVERY; LIVER; NONHUMAN; REPEATED DRUG DOSE; SINGLE DRUG DOSE; SPLEEN; VISCERAL LEISHMANIASIS;

ADMINISTRATION, ORAL; ANIMALS; ANTIPROTOZOAL AGENTS; BONE MARROW; CRICETINAE; DISEASE MODELS, ANIMAL; FEMALE; INHIBITORY CONCENTRATION 50; LEISHMANIASIS, VISCERAL; LIVER; MESOCRICETUS; PARASITE LOAD; PARASITIC SENSITIVITY TESTS; PHOSPHATIDYLCHOLINES; SPLEEN;

EID: 84867583796     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks273     Document Type: Article

References (30)

1. Desjeux P. The increase in risk factors for leishmaniasis worldwide. Trans R Soc Trop Med Hyg 2001; 95: 239-43.
2. Guerin PJ, Olliaro P, Sundar S et al. Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect Dis 2002; 2: 494-501.
3. Chappuis F, Sundar S, Hailu A et al. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat Rev Microbiol 2007; 5: 873-82.
4. Sundar S. Drug resistance in Indian visceral leishmaniasis. Trop Med Int Health 2001; 6: 849-54.
5. Chakravarty J, Sundar S. Drug resistance in leishmaniasis. J Glob Infect Dis 2010; 2: 167-76.
6. Dhillon GP, Sharma SN, Nair B. Kala-azar elimination programme in India. J Indian Med Assoc 2008; 106: 666-8.
7. Berdel WE. Ether lipids and derivatives as investigational anticancer drugs. A brief review. Onkologie 1990; 13: 245-50.
8. Unger C, Eibl H. Hexadecylphosphocholine: preclinical and the first clinical results of a new antitumor drug. Lipids 1991; 26: 1412-7.
9. Croft SL, Snowdon D, Yardley V. The activities of four anticancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei. J Antimicrob Chemother 1996; 38: 1041-7.
10. Escobar P, Yardley V, Croft SL. Activities of hexadecylphosphocholine (miltefosine), AmBisome, and sodium stibogluconate (Pentostam) against Leishmania donovani in immunodeficient scid mice. Antimicrob Agents Chemother 2001; 45: 1872-5.
11. Herwaldt BL. Miltefosine-the long-awaited therapy for visceral leishmaniasis? N Engl J Med 1999; 341: 1840-2.
12. Sundar S, Jha TK, Thakur CP et al. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 2002; 347: 1739-46.
13. Sindermann H, Engel J. Development of miltefosine as an oral treatment for leishmaniasis. Trans R Soc Trop Med Hyg 2006; 100 Suppl 1: S17-20.
14. Sundar S, Olliaro PL. Miltefosine in the treatment of leishmaniasis: clinical evidence for informed clinical risk management. Ther Clin Risk Manag 2007; 3: 733-40.
15. Kaufmann-Kolle P, Drevs J, Berger MR et al. Pharmacokinetic behavior and antineoplastic activity of liposomal hexadecylphosphocholine. Cancer Chemother Pharmacol 1994; 34: 393-8.
16. Dorlo TP, van Thiel PP, Huitema AD et al. Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients. Antimicrob Agents Chemother 2008; 52: 2855-60.
17. Olliaro PL. Drug combinations for visceral leishmaniasis. Curr Opin Infect Dis 2010; 23: 595-602.
18. Yardley V, Croft SL. A comparison of the activities of three amphotericin B lipid formulations against experimental visceral and cutaneous leishmaniasis. Int J Antimicrob Agents 2000; 13: 243-8.
19. Germonprez N, Maes L, Van Puyvelde L et al. In vitro and in vivo anti-leishmanial activity of triterpenoid saponins isolated from Maesa balansae and some chemical derivatives. J Med Chem 2005; 48: 32-7.
20. Vermeersch M, da Luz RI, Toté K et al. In vitro susceptibilities of Leishmania donovani promastigote and amastigote stages to antileishmanial reference drugs: practical relevance of stage-specific differences. Antimicrob Agents Chemother 2009; 53: 3855-9.
21. Maes L, Vanden Berghe D, Germonprez N et al. In vitro and in vivo activities of a triterpenoid saponin extract (PX-6518) from the plant Maesa balansae against visceral Leishmania species. Antimicrob Agents Chemother 2004; 48: 130-6.
22. Berman J, Bryceson AD, Croft S et al. Miltefosine: issues to be addressed in the future. Trans R Soc Trop Med Hyg 2006; 100 Suppl 1: S41-4.
23. Bryceson A. A policy for leishmaniasis with respect to the prevention and control of drug resistance. Trop Med Int Health 2001; 6: 928-34.
24. Croft SL, Engel J. Miltefosine-discovery of the antileishmanial activity of phospholipid derivatives. Trans R Soc Trop Med Hyg 2006; 100 Suppl 1: S4-8.
25. den Boer ML, Alvar J, Davidson RN et al. Developments in the treatment of visceral leishmaniasis. Expert Opin Emerg Drugs 2009; 14: 395-410.
26. Seifert K, Duchêne M, Wernsdorfer WH et al. Effects of miltefosine and other alkylphosphocholines on human intestinal parasite Entamoeba histolytica. Antimicrob Agents Chemother 2001; 45: 1505-10.
27. Berman JJ. Treatment of leishmaniasis with miltefosine: 2008 status. Expert Opin Drug Metab Toxicol 2008; 4: 1209-16.
28. Arndt D, Zeisig R, Fichtner I et al. Pharmacokinetics of sterically stabilized hexadecylphosphocholine liposomes versus conventional liposomes and free hexadecylphosphocholine in tumor-free and human breast carcinoma bearing mice. Breast Cancer Res Treat 1999; 58: 71-80.
29. Gupta S, Pal A, Vyas SP. Drug delivery strategies for therapy of visceral leishmaniasis. Expert Opin Drug Deliv 2010; 7: 371-402.
30. Cojean S, Houzé S, Haouchine D et al. Leishmania resistance to miltefosine associated with genetic marker. Emerg Infect Dis 2012; 18: 704-6.